Racial and Socioeconomic Disparities Are More Pronounced in Inflammatory Breast Cancer Than Other Breast Cancers
Table 3
Hazard ratios for inflammatory breast cancer patient mortality based on patient characteristics, Patterns of Care Study, 2004–2012.
Characteristic
At risk
Cause of death
Breast cancer
Any cause
Number
Number of deaths
HR (95% CI
Number of deaths
HR (95% CI
Total
170
91
121
Age at diagnosis, years
<50
50
26.4
25
1 (ref.)
30
1 (ref.)
50–59
49
34.1
31
2.05 (1.03–4.08)
37
1.89 (1.03–3.47)
60–69
36
22.6
18
1.15 (0.48–2.74)
24
1.28 (0.65–2.53)
≥70
35
16.9
17
1.92 (0.81–4.56)
30
2.53 (1.34–4.77)
Ancestry/ethnicity
European, non-Hispanic
81
68.4
36
1 (ref.)
48
1 (ref.)
African, non-Hispanic
68
22.4
43
1.76 (1.05–2.97)
56
1.86 (1.19–2.91)
Hispanic
14
7.6
8
1.14 (0.35–3.71)
11
1.57 (0.72–3.40)
Other
7
1.6
4
1.25 (0.67–2.33)
6
1.66 (0.88–3.13)
Piccirillo Comorbidity Score
None
55
33.0
26
1 (ref.)
35
1 (ref.)
Mild
68
40.6
38
0.55 (0.27–1.12)
48
0.48 (0.27–0.87)
Moderate
29
17.0
14
1.01 (0.43–2.41)
21
0.86 (0.39–1.86)
Severe
16
7.9
13
2.77 (1.35–5.69)
16
2.64 (1.32–5.27)
Unknown
2
1.6
0
—
1
0.88 (0.44–1.75)
Metastasis on presentation
Yes
63
31.1
49
3.20 (1.87–5.48)
59
2.97 (1.86–4.73)
No
107
68.9
42
1 (ref.)
62
1 (ref.)
ER/PR status
ER+ and/or PR+
87
49.1
38
0.55 (0.29–1.03)
56
0.54 (0.32–0.92)
ER− and PR−
70
42.9
45
1 (ref.)
54
1 (ref.)
Unknown
13
8.1
8
2.11 (0.76–5.83)
11
1.89 (0.71–5.05)
HER2 status
Positive
62
35.9
33
0.74 (0.40–1.36)
42
0.90 (0.55–1.49)
Negative
83
48.2
45
1 (ref.)
61
1 (ref.)
Unknown
25
16.0
13
0.84 (0.19–3.70)
18
0.80 (0.21–3.07)
Grade
Well or moderately differentiated
31
22.4
13
1 (ref.)
21
1 (ref.)
Poorly differentiated
112
66.0
64
1.84 (0.72–4.71)
84
1.83 (0.91–3.69)
Undifferentiated
6
1.8
2
0.46 (0.05–3.91)
2
0.38 (0.05–2.81)
Unknown
21
9.9
12
1.12 (0.39–3.20)
14
0.84 (0.36–1.96)
ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; ref., reference group. weighted based on sampling design. proportional hazards models adjusted for age, metastasis on presentation, ER/PR status, treatment, and sampling weights and strata within each study center.
